20S proteasome chymotrypsin-like and trypsin-like catalytic sites (20S CT-L and T-L sites)

The 20S proteasome is the catalytic core of the 26S proteasome complex, a multi-subunit enzyme responsible for the degradation of the majority of intracellular proteins. It contains three distinct types of catalytic sites: chymotrypsin-like (CT-L), trypsin-like (T-L), and caspase-like (C-L), which are housed within the beta-5 (PSMB5), beta-2 (PSMB7), and beta-1 (PSMB6) subunits, respectively. The CT-L site is the primary target for FDA-approved proteasome inhibitors such as bortezomib and carfilzomib, as it typically serves as the rate-limiting step for protein breakdown. However, research indicates that co-inhibition of the T-L site can significantly enhance the cytotoxic effects of these drugs and may help overcome therapeutic resistance in malignancies like multiple myeloma. By inhibiting these catalytic activities, drugs disrupt protein homeostasis, causing an accumulation of misfolded and regulatory proteins that triggers the unfolded protein response and leads to programmed cell death. This mechanism is a cornerstone of modern therapy for hematologic malignancies and continues to be explored for its potential in treating inflammatory and autoimmune conditions.

Other names

Proteasome subunit beta type-5 (PSMB5) and type-7 (PSMB7)Beta-5 and beta-2 subunits of the 20S proteasomeCT-L and T-L sites of the 20S core particle20S core particle catalytic sites

Drugs targeting these sites inhibit the proteolytic activity of the beta-5 (chymotrypsin-like) and beta-2 (trypsin-like) subunits within the 20S proteasome core. This inhibition prevents the degradation of regulatory proteins (such as IkappaB) and misfolded proteins, leading to the accumulation of polyubiquitinated proteins and the induction of the unfolded protein response (UPR). The resulting cellular stress triggers apoptosis, particularly in malignant cells that are highly dependent on efficient protein turnover.